OKYO Pharma Limited

NasdaqCM OKYO

OKYO Pharma Limited Price to Earnings Ratio (P/E) on December 30, 2024

OKYO Pharma Limited Price to Earnings Ratio (P/E) is NA on December 30, 2024, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

OKYO Pharma Limited 52-week high Price to Earnings Ratio (P/E) is NA on December 30, 2024, which is NA below the current Price to Earnings Ratio (P/E).
OKYO Pharma Limited 52-week low Price to Earnings Ratio (P/E) is NA on December 30, 2024, which is NA below the current Price to Earnings Ratio (P/E).
OKYO Pharma Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is NA.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: OKYO

OKYO Pharma Limited

CEO	Dr. Gary S. Jacob Ph.D.
IPO Date	May 17, 2022
Location	United Kingdom
Headquarters	55 Park Lane
Employees	8
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years